申请人:Adir et Compagnie
公开号:US06090837A1
公开(公告)日:2000-07-18
Compounds of formula (I): ##STR1## wherein: m is 0 to 3 inclusive, n is 0 to 3 and 2.ltoreq.m+n.ltoreq.3, p is 1 to 6 inclusive, X represents cyano or --CO--NR.sub.4 R.sub.5, R.sub.4 and R.sub.5 being selected from hydrogen, linear or branched (C.sub.1 -C.sub.6)-alkyl, (C.sub.3 -C.sub.7)-cycloalkyl, and aryl, R.sub.1 and R.sub.2 each independently represent hydrogen or linear or branched (C.sub.1 -C.sub.6)-alkyl, R.sub.3 represents hydrogen, optionally substituted phenyl, naphthyl or heteroaryl, or aryloxy or arylthio, or aryl or heteroaryl substituted by A'-Cy, A' and Cy being as defined in the description, and medicinal products containing the same which are useful as D.sub.3 receptor ligands.
式(I)的化合物:其中: m为0至3(含3),n为0至3且2≤m+n≤3,p为1至6(含6),X代表氰基或--CO--NR.sub.4 R.sub.5,其中R.sub.4和R.sub.5选择自氢、直链或支链(C.sub.1 -C.sub.6)-烷基、(C.sub.3 -C.sub.7)-环烷基和芳基,R.sub.1和R.sub.2各自独立地代表氢或直链或支链(C.sub.1 -C.sub.6)-烷基,R.sub.3代表氢、可选择取代的苯基、萘基或杂环芳基,或芳氧基或芳硫基,或由A'-Cy取代的芳基或杂环芳基,其中A'和Cy的定义如描述中所定义,并且含有这些化合物的药物制剂作为D.sub.3受体配体而有用。